At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 110 target
Drug / intervention
LBL-024 for Injection +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Multicenter Phase Ib/Ⅱ Study to Evaluate the Efficacy and Safety of LBL-024 in Combination With Paclitaxel Injection in Patients With Platinum-resistant Ovarian Cancer
In Brief
A Phase 2 clinical trial evaluating LBL-024 for Injection and Paclitaxel Injection for Ovarian Cancer. Currently recruiting, targeting 110 participants across 13 sites.
Detailed Summary
This trial is an open-label, multicenter phase Ib/II clinical study of LBL-024 combination therapy in patients with platinum-resistant ovarian cancer (OC),To evaluate the efficacy and safety of LBL-024 combination therapy in the treatment of advanced recurrent platinum-resistant ovarian cancer (OC) patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cancer
CountriesChina
Collaborators--
Timeline
Phase 2Recruiting
2026202720282029
First PostedJun 2025
Enrollment StartDec 2025
TodayJul 2026
Primary CompletionDec 2027
Study CompletionDec 2028
First PostedJun 29, 2025
Enrollment StartDec 2, 2025
Primary CompletionDec 25, 2027
Study CompletionDec 25, 2028
TodayJul 1, 2026
Enrollment to primary: 2.1 yearsPosted 1.0 years agoPrimary completion in 1.5 years
Interventions
LBL-024 for Injectiondrug
LBL-024 Intravenous infusion.
Paclitaxel Injectiondrug
Paclitaxel Intravenous infusion.